India · Delayed Price · Currency is INR Praj Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY 2026 delivered steady revenue but saw margin and profit declines due to lower export mix and project delays. Growth is expected from Engineering, HiPurity, and GenX segments, with policy support and new orders driving future performance.
-
Q2 and H1 FY26 saw strong execution amid headwinds, with revenue growth driven by international markets and a strategic pivot in engineering. Bioenergy remains the largest segment, while CBG and SAF show promise. GenX capacity utilization is delayed, and funding challenges persist.
-
Q1-FY26 saw a sharp decline in revenue and profit due to lower volumes, delayed execution, and higher costs, though order intake remained robust. Management expects margin recovery from H2, with growth focused on ethanol, CBG, and international markets.
Fiscal Year 2025
-
Q4 and FY25 saw lower revenue and profit YoY, but margin improved sequentially. Strong order backlog, international expansion, and new technologies in CBG and bioplastics position the business for future growth, despite execution delays and market uncertainties.
-
Order book hit a three-quarter high with 40% international share, but Q3 margins and profits declined due to sales mix and GenX facility delays. Leadership transition and new JV for CBG plants signal strategic growth, with international and SAF opportunities expected to drive future expansion.
-
Q2 FY25 saw lower revenue and profit YoY, but order intake and backlog remain strong, especially in bioenergy and services. The company is capitalizing on global biofuel demand, new biopolymer capabilities, and expects margin stability and revenue growth in coming quarters.
-
Q1 FY25 saw resilient profit growth despite lower revenue, with strong export and engineering momentum offsetting domestic bioenergy headwinds from policy uncertainty. Order backlog and margins improved, and management remains optimistic for higher order booking and revenue ramp-up in FY25.